Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors

Abstract

Get full access to this article

View all access options for this article.

References

Başcı

Ata

Altıntaş

, et al. Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Practice 2020. DOI: 10.1177/1078155220953198.

Rothman

Greenland

Modern epidemiology. 2nd ed. Philadelphia, PA: Lippincott-Raven Publishers, 1998.

Breccia

Girmenia

Latagliata

, et al. Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. Mediterr J Hematol Infect Dis 2011; 3: e2011021.

Shojaei

Salari

COVID-19 and off label use of drugs: an ethical viewpoint. 2020. DARU J Pharm Sci. 2020. DOI: 10.1007/s40199-020-00351-y